Skip to main content
. Author manuscript; available in PMC: 2021 Jul 27.
Published in final edited form as: J Clin Immunol. 2020 Jan 15;40(2):359–366. doi: 10.1007/s10875-019-00740-2

Figure 2. ROS and IL-6 production in blood cells of CARD9 deficient patient.

Figure 2.

A. Normal NADPH oxidase activity in the patient’s neutrophils after activation with unopsonized zymosan (Z) (5μg/ml), as assessed by the monitoring of luminol-dependent chemiluminescence for 60 minutes at room temperature. B. Interleukin 6 (IL-6) production in the supernatants of cultured whole blood cells stimulated for 48 hours with unopsonized zymosan (Z) (5 μg/ml); LPS from Salmonella Minnesota (100ng/ml) or phorbol 12-myristate 13-acetate (PMA) – Ionomycin (I), 10−7 M and 10−5 M), as measured by enzyme-linked immunosorbent assay (ELISA). The results are representative from one experiment performed using duplicate samples involving two healthy age matched controls.